A Single Arm Trial Evaluating the BARD Lutonix Drug-Coated Balloon (LTX DCB) for Treatment of Femoropopliteal Arteries

NACompletedINTERVENTIONAL
Enrollment

148

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

October 31, 2018

Study Completion Date

August 31, 2020

Conditions
Femoral Artery StenosisFemoral Artery OcclusionStenosis of Popliteal ArteriesOcclusion of Popliteal Arteries
Interventions
DEVICE

LTX DCB

Treatment with a drug-coated balloon

Trial Locations (14)

100038

Beijing Shijitan Hospital. CMU, Beijing

100853

Chinese- PLA General Hospital, Beijing

116011

The First Affiliated Hospital of Dalian Medical University, Dalian

200011

Shanghai Ninth People's Hosptial , Shanghai JiaoTong University School of Medicine, Shanghai

200032

Zhongshan Hospital Fudan University, Shanghai

200127

RENJI Hospital Shanghai Jiaotong University School of Medicine, Shanghai

210008

Nanjing Drum Tower Hospital,The Affiliated Hospital of Nanjing University Medical School, Nanjing

250012

Qilu Hospital of Shandong University, Jinan

266003

The Affiliated Hospital of Qingdao University, Qingdao

350005

The First Affiliated Hospital of Fujian Medical University, Fuzhou

510260

The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou

610041

West China Hospital, Sichuan University, Chengdu

050000

The Second Hospital of Hebei Medical University, Shijiazhuang

Unknown

General Hospital of Tianjin Medical University, Tianjin

Sponsors

Lead Sponsor

All Listed Sponsors
lead

C. R. Bard

INDUSTRY

NCT02720003 - A Single Arm Trial Evaluating the BARD Lutonix Drug-Coated Balloon (LTX DCB) for Treatment of Femoropopliteal Arteries | Biotech Hunter | Biotech Hunter